1. RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
- Author
-
Huanxiang Chen, Hongyang Liu, Chenxing Zhang, Nan Xiao, Yang Li, Xiangzhuan Zhao, Ruike Zhang, Huihui Gu, Qiaozhen Kang, and Junhu Wan
- Subjects
cancer ,drug resistance ,inhibitor ,RNA methylation ,Medicine (General) ,R5-920 - Abstract
Abstract RNA methylation is widespread in nature. Abnormal expression of proteins associated with RNA methylation is strongly associated with a number of human diseases including cancer. Increasing evidence suggests that targeting RNA methylation holds promise for cancer treatment. This review specifically describes several common RNA modifications, such as the relatively well‐studied N6‐methyladenosine, as well as 5‐methylcytosine and pseudouridine (Ψ). The regulatory factors involved in these modifications and their roles in RNA are also comprehensively discussed. We summarise the diverse regulatory functions of these modifications across different types of RNAs. Furthermore, we elucidate the structural characteristics of these modifications along with the development of specific inhibitors targeting them. Additionally, recent advancements in small molecule inhibitors targeting RNA modifications are presented to underscore their immense potential and clinical significance in enhancing therapeutic efficacy against cancer. Key Points In this paper, several important types of RNA modifications and their related regulatory factors are systematically summarised. Several regulatory factors related to RNA modification types were associated with cancer progression, and their relationships with cancer cell migration, invasion, drug resistance and immune environment were summarised. In this paper, the inhibitors targeting different regulators that have been proposed in recent studies are summarised in detail, which is of great significance for the development of RNA modification regulators and cancer treatment in the future.
- Published
- 2024
- Full Text
- View/download PDF